Insmed Inc (INSM)vsRoivant Sciences Ltd (ROIV)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
ROIV
Roivant Sciences Ltd
$27.36
+1.82%
HEALTHCARE · Cap: $19.23B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 4456% more annual revenue ($606.42M vs $13.31M). ROIV leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
ROIV
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% margin — thin
ROE of -19.1% — below average capital efficiency
Revenue declined 77.8%
Earnings declined 96.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : ROIV
The strongest argument for ROIV centers on Debt/Equity, Altman Z-Score.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : ROIV
The primary concerns for ROIV are Profit Margin, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while ROIV is a value play — different risk/reward profiles.
ROIV carries more volatility with a beta of 1.21 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ROIV generates stronger free cash flow (-201M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Roivant Sciences Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Roivant Sciences Ltd (ROIV) is a pioneering biopharmaceutical company focused on transforming the way therapies are developed and commercialized, utilizing a distinctive model that leverages proprietary technologies. With a diverse pipeline addressing critical unmet needs in neurology, immunology, and rare diseases, Roivant aims to streamline the drug development process, thereby reducing time and costs associated with bringing new therapies to market. The company's strong leadership team and strategic partnerships further enhance its potential to disrupt the healthcare landscape, creating significant value for investors while improving patient outcomes.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?